First, in the updated United States and European ACS guidelines, ACE inhibitors/ARBs received a class I recommendation only for ACS patients with heart failure, hypertension, or diabetes, and beta-blockers received a class I recommendation only for ACS patients with heart failure[19, 20]. Here, ACE is linked to Hypertension.